Pharmaceutical

Santa Ana Bio secures $168m for inflammatory disease treatments

Precision immunology company Santa Ana Bio has announced a substantial funding injection of $168m through Series A and B financing rounds.

Jun 16, 2024 - 04:00
Santa Ana Bio secures $168m for inflammatory disease treatments
Precision immunology company Santa Ana Bio has announced a substantial funding injection of $168m through Series A and B financing rounds.
Read the original article

Tags:

Previous Article

Pre-diabetes rates increase amidst a renaissance for type 2 diabetes research

Next Article

Suven Pharmaceuticals to gain controlling stake in Sapala Organics

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Biogen discontinues Aduhelm to focus on Leqembi for Alzheimer’s disease

Biogen discontinues Aduhelm to focus on Leqembi for Alz...

Feb 28, 2024

STAT+: Inside Ascension’s legal fight with a Texas agency over caring for the poor

STAT+: Inside Ascension’s legal fight with a Texas agen...

Jan 2, 2024

Polio cases derived from new oral vaccine reported for first time

Polio cases derived from new oral vaccine reported for ...

Mar 19, 2023